Achieve Life Sciences DEF 14A: Executive Compensation Details
Ticker: ACHV · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 949858
| Field | Detail |
|---|---|
| Company | Achieve Life Sciences, Inc. (ACHV) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: ACHV
TL;DR
ACHV proxy statement out, details exec pay & equity awards for 2024.
AI Summary
Achieve Life Sciences, Inc. filed a DEF 14A on April 28, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to individuals such as Richard Stewart and John Bencich, with specific dates and values related to their compensation packages.
Why It Matters
This filing provides shareholders with crucial information regarding how executive compensation is structured and awarded, impacting company performance and investor confidence.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but can sometimes reveal compensation practices or governance issues that may affect investor sentiment.
Key Players & Entities
- Achieve Life Sciences, Inc. (company) — Filer
- Richard Stewart (person) — Member of Board of Directors
- John Bencich (person) — Member of Board of Directors
- 2024-12-31 (date) — Fiscal Year End
- 20250428 (date) — Filing Date
FAQ
What is the primary purpose of this DEF 14A filing for Achieve Life Sciences, Inc.?
The primary purpose is to provide shareholders with information regarding the company's annual meeting, including details on executive compensation, director nominations, and other corporate governance matters.
Who are some of the key individuals mentioned in relation to equity awards?
Key individuals mentioned in relation to equity awards include Richard Stewart and John Bencich.
What is the fiscal year end for Achieve Life Sciences, Inc. as stated in the filing?
The fiscal year end for Achieve Life Sciences, Inc. is December 31st.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 28, 2025.
What were the previous names of Achieve Life Sciences, Inc.?
Achieve Life Sciences, Inc. was formerly known as OncoGenex Pharmaceuticals, Inc. and Sonus Pharmaceuticals Inc.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 by Richard Stewart regarding ACHIEVE LIFE SCIENCES, INC. (ACHV).